A 2019 study found that patients with early-stage psychotic disorders had lower levels of CB1-R (Cannabinoid Receptor – 1) compared to healthy individuals. These findings suggest that targeting CB1R with cannabis-based products could potentially treat psychotic disorders. Interestingly, reductions in CB1R levels were associated with greater symptom severity and poorer cognitive functioning but only in male patients. More research is needed into the intersections of gender and psychotic disorders.
View this review (yellow link) or download:
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode PsychosisDownload
This paper is also stored here: http://bit.ly/2XEkpfV inside the CED Foundation Archive
To explore related information, click the keywords below: